Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of ligandrol (lgd-4033 capsule) in China. Welcome to wholesale bulk high quality ligandrol (lgd-4033 capsule) for sale here from our factory. Good service and reasonable price are available.
Ligandrol (LGD-4033) is an oral selective androgen receptor modulator (SARM) that selectively activates androgen receptors in skeletal muscle and bone tissues to promote anabolic processes, increasing lean body mass and strength while exhibiting minimal androgenic activity in non-target tissues such as the prostate and liver. Bloomtechz supplies research-grade LGD-4033 capsules manufactured under stringent quality control protocols, with each batch accompanied by a comprehensive Certificate of Analysis (COA) verifying identity, purity, and absence of contaminants, supported by one-on-one dedicated technical assistance from our professional sales team and mature technical specialists for legitimate research applications.
|
|
|
LGD-4033 COA
 |
||
| Certificate of Analysis | ||
| Compound name | LGD-4033 | |
| Grade | Pharmaceutical grade | |
| CAS No. | 1165910-22-4 | |
| Quantity | 18g | |
| Packaging standard | PE bag+Al foil bag | |
| Manufacturer | Shaanxi BLOOM TECH Co., Ltd | |
| Lot No. | 202601090055 | |
| MFG | Jan 9th 2026 | |
| EXP | Jan 8th 2029 | |
| Structure |
|
|
| Item | Enterprise standard | Analysis result |
| Appearance | White or almost white powder | Conformed |
| Water content | ≤5.0% | 0.55% |
| Loss on drying | ≤1.0% | 0.74% |
| Heavy Metals | Pb≤0.5ppm | N.D. |
| As≤0.5ppm | N.D. | |
| Hg≤0.5ppm | N.D. | |
| Cd≤0.5ppm | N.D. | |
| Purity (HPLC) | ≥99.0% | 99.54% |
| Single impurity | <0.8% | 0.47% |
| Total microbial count | ≤750cfu/g | 653 |
| E. Coli | ≤2MPN/g | N.D. |
| Salmonella | N.D. | N.D. |
| Ethanol (by GC) | ≤5000ppm | 520ppm |
| Storage | Store in a sealed, dark, and dry place below -20°C | |
|
|
||
Core Potential in the Treatment of Muscular Atrophy
Muscular atrophy refers to a syndrome characterized by reduced muscle mass and decreased muscle strength caused by various factors such as aging, disease, and trauma, which severely impairs patients' motor function and quality of life. Ligandrol (LGD-4033 Capsule) was originally developed to address this clinical need. Its core mechanism of action lies in specifically activating androgen receptors in muscle tissue to promote protein synthesis and inhibit muscle catabolism, while alleviating oxidative stress-induced damage to muscle cells and enhancing muscle cell viability.In preclinical studies, it has demonstrated ameliorative effects on muscular atrophy caused by multiple etiologies.
For age-related sarcopenia, human androgen levels decline with age, leading to gradual muscle loss, and it can reverse this process by mimicking the anabolic effects of androgens. For muscular dystrophy, it can delay the progression of muscle fibrosis and improve patients' motor function by enhancing the anti-apoptotic capacity of muscle cells.Among cancer patients, radiotherapy and chemotherapy often trigger severe muscle wasting; in vitro experiments have shown that it can reduce the myotoxicity and apoptosis induced by chemotherapeutic drugs such as cisplatin, providing support for cancer patients to maintain muscle function.
Preventive and Therapeutic Value for Osteoporosis
Osteoporosis is characterized by reduced bone mass and impaired bone microstructure, which easily increases the risk of fractures, and is particularly prevalent in middle-aged and elderly populations and patients with chronic diseases. By regulating bone metabolic pathways, it exhibits significant bone-protective effects, offering a new direction for the prevention and treatment of osteoporosis.Its mechanism of action is mainly reflected in two aspects: promoting bone formation and inhibiting bone resorption. As an androgen receptor agonist, product can specifically act on osteoblasts in bone tissue, enhance osteoblast activity, promote periosteal bone formation, and improve the microstructure of bone tissue, thereby increasing bone mineral density (BMD).
At the same time, it can inhibit the bone resorption function of osteoclasts, reduce bone loss, and maintain bone homeostasis. This dual regulatory effect distinguishes it from traditional anti-osteoporotic drugs, as it can both increase bone formation and preserve existing bone mass.Preclinical studies have shown that LGD-4033 can significantly improve the bone mechanical properties of experimental animals and reduce the incidence of fractures. For secondary osteoporosis caused by hormonal changes, chronic diseases or drug therapy, such as bone damage induced by long-term glucocorticoid use, Ligandrol can also exert a protective effect by regulating bone metabolic pathways.
Application Prospects in the Prevention of Cachexia
Cachexia is a complex metabolic disorder syndrome common in patients with severe diseases such as advanced cancer, AIDS, chronic kidney disease, and chronic obstructive pulmonary disease. It is characterized by progressive weight loss, muscular atrophy, and fat depletion, which seriously affects patients' treatment tolerance and survival time. At present, there is a lack of effective clinical treatment methods, and ithas become a potential drug for the prevention and intervention of cachexia by virtue of its strong muscle synthesis capacity.The core pathological mechanism of cachexia is metabolic imbalance caused by excessive release of inflammatory factors, leading to hyperactive protein catabolism and inhibited anabolism.
By activating androgen receptors in muscle tissue, it significantly enhances protein synthesis efficiency, counteracts inflammation factor-mediated muscle breakdown, and at the same time increases patients' appetite and energy intake to improve nutritional status. For cancer patients, it can not only alleviate muscle wasting caused by radiotherapy and chemotherapy, but also improve physical fitness and treatment compliance; in AIDS patients, it can relieve muscle atrophy and immune function decline induced by viral infection, and improve quality of life.
Potential Anti-diabetic Effects and Mechanisms
In addition to its muscle and bone protective effects, studies in recent years have found that the product also has certain anti-diabetic activity, especially showing potential value in improving the symptoms of type 2 diabetes. Its mechanism of action mainly focuses on pancreatic islet function protection and insulin sensitivity regulation.Impaired pancreatic islet β-cell function is one of the core factors in the occurrence and development of type 2 diabetes. Itcan protect pancreatic islet β-cell function by antagonizing the damage of harmful substances to pancreatic islets.In vitro experiments have confirmed that it can inhibit streptozotocin-induced pancreatic islet cell damage,
reduce cell apoptosis, and at the same time promote insulin secretion to improve islet secretory function. In addition, Ligandrol (LGD-4033 Capsule) can enhance the body's insulin sensitivity, promote the uptake and utilization of glucose by peripheral tissues (such as muscle and fat), reduce fasting blood glucose levels, and alleviate insulin resistance.
Chemical Nature and Molecular Design
LGD-4033 is a non-steroidal selective androgen receptor modulator (SARM), with the molecular formula C₁₄H₁₂F₆N₂O and a molecular weight of 338.25 g/mol. Its core structure consists of a pyrrolidine ring and two trifluoromethyl groups, which give it high lipid solubility and stability. Unlike traditional anabolic steroids (such as testosterone), LGD-4033 selectively activates androgen receptors in muscles and bones, avoiding excessive stimulation of non-target tissues such as the prostate and liver, thereby reducing side effects (such as prostate hypertrophy, hair loss, etc.).
Manufacturing Process and Key Steps
The synthesis of LGD-4033 begins with basic chemical raw materials, such as cesium fluoride, trimethylsilane, potassium hydroxide, etc. These raw materials undergo chemical reactions to generate intermediates, which are then further synthesized into the target molecule. The purity of key intermediates directly affects the quality of the final product, so strict testing using high-performance liquid chromatography (HPLC) or gas chromatography (GC) is necessary.
The synthesis of LGD-4033 involves multiple organic reactions, including fluorination, cyclization, nitration, etc. Each reaction step requires specific temperature, pressure, and catalyst conditions to ensure yield and purity. For example, the introduction of the trifluoromethyl group needs to be carried out at a low temperature using fluorinating reagents to avoid the occurrence of side reactions.
The crude product LGD-4033 needs to be purified by recrystallization or column chromatography to remove impurities. The selection of crystallization solvents (such as ethanol, acetone) should take into account solubility and crystallization efficiency. The purified product must reach a purity of ≥ 98% to meet the requirements of research or clinical applications.
Ingredient Selection: LGD-4033 is a hydrophobic powder, and it needs to be mixed with excipients (such as microcrystalline cellulose, lactose) to improve flowability. Capsule shells are usually made of gelatin or hydroxypropyl methylcellulose (HPMC) to ensure no drug interactions.
Filling Process: Use an automatic capsule filling machine to control the content error of each capsule within ±5%. The filling environment should maintain a low humidity (RH < 30%) to prevent powder from absorbing moisture and caking.
Packaging and Storage: The finished capsules need to be sealed in aluminum foil blister or high-density polyethylene (HDPE) bottles, stored in a light-protected environment at -20°C, and kept for a validity period of 2-3 years.
Quality Control and Standards
Purity test
The purity of Ligandrol (LGD-4033 Capsule) was determined by HPLC. The main peak area accounted for ≥ 98%, single impurity ≤ 0.5%, and total impurity ≤ 1.0%.
Residual solvent analysis
The residual amount of organic solvents (such as methanol and dichloromethane) used in the synthesis process should meet the international standard for pharmaceutical excipients (ICH guidelines), such as methanol residue ≤ 3000 ppm.
Microbial limit
For non sterile preparations, the total number of bacteria should be controlled ≤ 1000 cfu/g, mold and yeast ≤ 100 cfu/g to ensure product safety.
Stability test
Accelerated stability test (40 ℃/75% RH) and long-term stability test (25 ℃/60% RH) shall prove that the quality of the product is stable within the validity period, and the degradation products shall not exceed 5% of the marked amount.
Legal Status
LGD-4033 is listed as a prohibited substance by the World Anti-Doping Agency (WADA), and athletes using it may face suspension penalties. Its clinical research is limited to the treatment of diseases such as muscle atrophy and osteoporosis, and its non-medical use is illegal.
Production License
Producing LGD-4033 requires obtaining GMP certification for pharmaceutical production and approval from drug regulatory authorities (such as FDA, EMA). Unapproved production and sales may involve criminal liability.
Intellectual Property Protection
The patent for LGD-4033 is held by Viking Therapeutics. Other enterprises need to obtain authorization to legally produce it. Patent infringement lawsuits are common risks in the industry, and risks can be reduced through patent avoidance design or cooperative development.
Market Status and Future Trends
Market Demand
LGD-4033 has a strong demand in the fitness and sports fields, but there are issues of inconsistent quality in illegal sales channels. Research-grade products (with a purity of ≥ 98%) are more expensive (about 500-1000 yuan/g), while industrial-grade products (with a purity of 90-95%) are cheaper (about 200-500 yuan/g).
Technological Innovation
Continuous-flow chemical technology can improve synthesis efficiency and reduce solvent usage; biocatalytic synthesis may become a new direction for green manufacturing. In addition, new formulations (such as nanocrystals, liposomes) can improve the oral absorption and bioavailability of LGD-4033.
Clinical Application Expansion
In addition to muscle atrophy and osteoporosis, the potential of LGD-4033 in chronic obstructive pulmonary disease (COPD), heart failure, etc. is being studied. More clinical trials are needed to verify its safety and efficacy in the future.
Analytical Methods and Validation
Content determination
HPLC method: Using a C18 chromatographic column, with acetonitrile-water (containing 0.1% formic acid) as the mobile phase, at a flow rate of 1.0 mL/min, and the detection wavelength at 210 nm. This method can accurately determine the content of Ligandrol (LGD-4033 Capsule), with a linear range of 0.1-100 μg/mL, and a recovery rate of 98%-102%.
UV-Vis spectrophotometry: Measuring the absorbance at 245 nm wavelength, suitable for rapid screening. However, attention should be paid to the interference of excipients, and correction should be made through the standard addition method.
Contaminant inspection
HPLC-DAD method: Monitoring the ultraviolet spectra of impurity peaks through a diode array detector (DAD) to ensure the retention time difference between impurities and the main peak ≥ 0.5 minutes.
LC-MS method: For low-level impurities (such as below 0.1%), qualitative and quantitative analysis should be conducted using liquid chromatography-mass spectrometry (LC-MS) technology.
Solubility determination
Basket method/Whisker method: Using 0.1 M hydrochloric acid solution as the dissolution medium, with a rotation speed of 50 rpm, the dissolution amount after 30 minutes should be ≥ 80%. This method can simulate the absorption process in the body and evaluate the quality of the preparation.
Microbial testing
Petri dish method: Using TSA (bacteriological agar) medium, cultivating at 30-35℃ for 3-5 days, counting the total bacterial count.
Sabouraud's glucose agar medium: Used for mold and yeast detection, cultivating at 20-25℃ for 5-7 days.
References
Basaria, S., Collins, L., Dillon, E. L., Orwoll, K., Storer, T. W., Miciek, R., Ulloor, J., Zhang, A., Eder, R., Zientek, H., Gordon, G., Kazmi, S., Sheffield-Moore, M., & Bhasin, S. (2013). Safety, pharmacokinetics, and efficacy of a novel selective androgen receptor modulator (SARM), LGD-4033, in healthy young men. Journal of Clinical Endocrinology & Metabolism, 98(1), 136–146.
Dalton, J. T., Barnette, K. G., Bohl, C. E., Hancock, M. L., Rodriguez, D., Dodson, S. T., & Miller, D. D. (2011). The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: Results of a double-blind, placebo-controlled phase II trial. Journal of Cachexia, Sarcopenia and Muscle, 2(3), 153–161.
European Medicines Agency. (2023). Guideline on the limits of genotoxic impurities (ICH M7(R2)). EMA.
Kicman, A. T. (2008). Pharmacology of anabolic steroids. British Journal of Pharmacology, 154(3), 502–521.
World Anti-Doping Agency. (2024). The World Anti-Doping Code: The 2024 prohibited list. WADA.
Frequently Asked Questions
FAQ 1: What is the purity specification of your LGD-4033 capsules, and do you provide full analytical documentation?
+
-
Our Ligandrol capsules are manufactured using API with ≥99.0% purity, verified by HPLC and NMR analysis. Each batch is accompanied by a complete Certificate of Analysis (COA) confirming identity, assay, and absence of key impurities. As a source manufacturer, Bloomtechz maintains full traceability from raw material through final encapsulation, ensuring compliance with research-grade quality standards.
FAQ 2: Why are capsules preferred over loose powder for LGD-4033 handling?
+
-
Capsule encapsulation provides precise, pre-measured dosing that eliminates weighing errors inherent to loose powder handling. The sealed format protects the hygroscopic compound from moisture degradation, improves portability, and removes the need for solvent-based dosing methods that can cause irritation. Our hard gelatin capsules meet pharmacopeial specifications for weight uniformity and moisture content (13–16% LOD), ensuring consistent content delivery.
FAQ 3: What are your minimum order quantities and lead times for bulk procurement?
+
-
We accommodate orders ranging from small research quantities to commercial-scale volumes. Standard lead times are 3–7 business days for in-stock specifications, with custom encapsulation runs scheduled within 10–15 business days. Our mature production control systems support scalable fulfillment while maintaining strict batch-to-batch consistency. All shipments include COA, MSDS, and commercial documentation for seamless customs clearance.
FAQ 4: How do you ensure product stability during international shipping?
+
-
Given LGD-4033's hygroscopic nature and recommended -20°C storage under inert atmosphere, our packaging employs moisture-barrier aluminum foil bags with desiccant packs, sealed in insulated containers with cold-chain options for temperature-sensitive shipments. Our logistics partnerships include temperature-controlled freight services, and all packaging is validated to maintain product integrity through standard international transit durations.
FAQ 5: What technical support is available for research institutions evaluating your LGD-4033 supply?
+
-
Bloomtechz provides one-on-one dedicated account management with direct access to our technical team for formulation guidance, stability data requests, and analytical method support. Our professional sales team coordinates sample requests, custom specification discussions, and regulatory documentation needs, ensuring a streamlined procurement process from initial inquiry through ongoing supply arrangements.
Hot Tags: ligandrol (lgd-4033 capsule), suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale